Operose Advisors’s AbbVie ABBV Stock Holding History

Operose Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.16M	Sell	4,615 -210	-4%	-$45.2K	0.22%	57
2026 Q1	$1.05M	Buy	4,825 +360	+8%	+$79.9K	0.24%	52
2025 Q4	$1.02M	Hold	4,465	–	–	0.24%	53
2025 Q3	$1.03M	Hold	4,465	–	–	0.26%	50
2025 Q2	$829K	Hold	4,465	–	–	0.23%	56
2025 Q1	$936K	Sell	4,465 -1,106	-20%	-$215K	0.31%	45
2024 Q4	$990K	Buy	5,571 +1,204	+28%	+$221K	0.34%	40
2024 Q3	$862K	Buy	4,367 +34	+0.8%	+$6.35K	0.28%	50
2024 Q2	$743K	Sell	4,333 -250	-5%	-$41.4K	0.26%	51
2024 Q1	$835K	Buy	4,583 +2,630	+135%	+$453K	0.28%	49
2023 Q4	$303K	Sell	1,953 -467	-19%	-$68.1K	0.12%	85
2023 Q3	$361K	Buy	2,420 +834	+53%	+$122K	0.14%	69
2023 Q2	$214K	Hold	1,586	–	–	0.1%	80
2023 Q1	$253K	Sell	1,586 -549	-26%	-$83.9K	0.13%	57
2022 Q4	$345K	Buy	2,135 +549	+35%	+$84.2K	0.18%	43
2022 Q3	$213K	Buy	1,586 +136	+9%	+$19.5K	0.14%	56
2022 Q2	$222K	Hold	1,450	–	–	0.16%	51
2022 Q1	$235K	Hold	1,450	–	–	0.16%	56
2021 Q4	$196K	Buy	+1,450	New	+$171K	0.16%	58

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Operose Advisors's ABBV Position: Q2 2026 in Review

Operose Advisors reduced its AbbVie (ABBV) stake by 4.4% in Q2 2026, selling an estimated $45.2K and leaving 4,615 shares worth $1.16M. The position accounts for 0.22% of the portfolio, ranked #57.

Operose Advisors first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Operose Advisors held 4,615 shares of AbbVie worth $1.16M as of Q2 2026.
Operose Advisors sold 210 AbbVie shares in Q2 2026, an estimated $45.2K.
AbbVie made up 0.22% of Operose Advisors's portfolio in Q2 2026, its #57 holding.
Operose Advisors first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.